Clinical Handbook of Psychotropic Drugs
Hogrefe Publishing (Verlag)
978-0-88937-561-1 (ISBN)
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
* Independent, unbiased, up-to-date - now with esketamine (Spravato)
* Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine
* New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar
* Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
* Potential interactions and side effects summarized in comparison charts
* With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
* Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
-------------------------------------------------------------------------------------------
New in this edition:
* Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions
* Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies
* Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations
* Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes
* Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene)
* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine
* New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar
Ric M. Procyshyn; BScPharm, MSc, PharmD, PhD; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada. Kalyna Z. Bezchlibnyk-Butler; BScPharm, FCSHP; Toronto, ON, Canada. J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine
Dopamine Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine
Reuptake Inhibitor (SNRI) * Serotonin-2 Antagonists / Reuptake
Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor
(SPARI) * Serotonin Modulator and Stimulator (SMS) * Noradrenergic /
Specific Serotonergic Antidepressants (NaSSA) * Nonselective
Cyclic Antidepressants * Monoamine Oxidase Inhibitors * Reversible
Inhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B)
Inhibitors (MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants
on Neurotransmitters / Receptors * Pharmacological
Effects of Antidepressants on Neurotransmitters / Receptors *
Frequency of Adverse Reactions to Antidepressants at Therapeutic
Doses * Antidepressant Doses and Pharmacokinetics * Switching
Antidepressants * Antidepressant Augmentation Strategies
Electroconvulsive Therapy (ECT)
Bright Light Therapy (BLT)
Repetitive Transcranial Magnetic Stimulation (rTMS)
Antipsychotics
Second-Generation Antipsychotics / SGAs * Third-Generation
Antipsychotic / TGA * 5-HT21 Inverse Agonist Antipsychotic * First-
Generation Antipsychotics / FGAs * Effects of Antipsychotics on
Neurotransmitters / Receptors * Pharmacological Effects of Antipsychotics
on Neurotransmitters / Receptor Subtypes * Relative Tolerability
Profiles of Anti-psychotics * Frequency of Adverse Reactions
to Antipsychotics at Therapeutic Doses * Antipsychotic Doses and
Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of
Long-Acting IM Antipsychotics * Switching Antipsychotics *
Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects and Their
Management
Extrapyramidal Adverse Effects of Antipsychotics * Treatment
Options for Extrapyramidal Side Effects * Effects on Extrapyramidal
Symptoms * Comparison of Agents for Treating Acute Extrapyramidal
Side Effects * Doses and Pharmacokinetics of Agents for Treating
Acute Extrapyramidal Side Effects
Anxiolytic (Antianxiety) Agents
Benzodiazepines * Comparison of the Benzodiazepines * Buspirone
Hypnotics / Sedatives
L-Tryptophan * Comparison of Hypnotics / Sedatives
Mood Stabilizers
Lithium * Anticonvulsants * Comparison of Anticonvulsants *
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic
Doses
Drugs for ADHD
Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD *
2 Agonists * Augmentation Strategies in ADHD
Drugs for Treatment of Dementia
Cholinesterase Inhibitors * Memantine * Comparison of Drugs for
Treatment of Dementia
Sex-Drive Depressants
Comparison of Sex-Drive Depressants
Drugs of Abuse
Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols
* Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam
(Rohypnol) * Nicotine / Tobacco
Treatment of Substance Use Disorders
Acamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone *
Pharmacotherapy for Nicotine / Tobacco Use Disorder * Comparison
of Treatments for Nicotine / Tobacco Use Disorder
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents * Anti-Inflammatory Agents * Dopaminergic
Agents * GABA Agents / Anticonvulsants *
Hormones * NMDA Agents * 5-HT3 Antagonists * Miscellaneous
Natural Health Products
Pharmacogenomic Information for Common Psychotropic Drugs
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient Information Sheets
Appendix:
Neuroscience-Based Nomenclature
Index of Drugs
| Erscheinungsdatum | 12.06.2019 |
|---|---|
| Verlagsort | Toronto |
| Sprache | englisch |
| Maße | 279 x 216 mm |
| Einbandart | Spiralbindung |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Medizin / Pharmazie ► Pflege | |
| Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
| Schlagworte | Pharmacy • Psychopharmacology • Psychotropic drugs |
| ISBN-10 | 0-88937-561-5 / 0889375615 |
| ISBN-13 | 978-0-88937-561-1 / 9780889375611 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
